KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Work In Process: 2011-2013

Historic Work In Process for Pacira BioSciences (PCRX) over the last 1 years, with Jun 2013 value amounting to $6.5 million.

  • Pacira BioSciences' Work In Process rose 355.94% to $6.5 million in Q2 2013 from the same period last year, while for Jun 2013 it was $6.5 million, marking a year-over-year increase of 355.94%. This contributed to the annual value of $6.0 million for FY2012, which is 6128.12% up from last year.
  • Latest data reveals that Pacira BioSciences reported Work In Process of $6.5 million as of Q2 2013, which was up 54.09% from $4.2 million recorded in Q1 2013.
  • Pacira BioSciences' 5-year Work In Process high stood at $6.5 million for Q2 2013, and its period low was $96,000 during Q4 2011.
  • Moreover, its 3-year median value for Work In Process was $2.8 million (2012), whereas its average is $3.2 million.
  • Data for Pacira BioSciences' Work In Process shows a peak YoY surged of 6,128.12% (in 2012) over the last 5 years.
  • Over the past 3 years, Pacira BioSciences' Work In Process (Quarterly) stood at $96,000 in 2011, then spiked by 6,128.12% to $6.0 million in 2012, then spiked by 355.94% to $6.5 million in 2013.
  • Its Work In Process was $6.5 million in Q2 2013, compared to $4.2 million in Q1 2013 and $6.0 million in Q4 2012.